Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Receivables - Accured: 2022-2024

Historic Receivables - Accured for Crinetics Pharmaceuticals (CRNX) over the last 3 years, with Dec 2024 value amounting to $8.3 million.

  • Crinetics Pharmaceuticals' Receivables - Accured was N/A to $6.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.3 million, marking a year-over-year change of. This contributed to the annual value of $8.3 million for FY2024, which is 167.74% up from last year.
  • According to the latest figures from FY2024, Crinetics Pharmaceuticals' Receivables - Accured is $8.3 million, which was up 167.74% from $3.1 million recorded in FY2023.
  • Crinetics Pharmaceuticals' 5-year Receivables - Accured high stood at $8.3 million for FY2024, and its period low was $1.4 million during FY2022.
  • For the 3-year period, Crinetics Pharmaceuticals' Receivables - Accured averaged around $4.3 million, with its median value being $3.1 million (2023).
  • Data for Crinetics Pharmaceuticals' Receivables - Accured shows a peak YoY skyrocketed of 167.74% (in 2024) over the last 5 years.
  • Crinetics Pharmaceuticals' Receivables - Accured (Yearly) stood at $1.4 million in 2022, then spiked by 121.43% to $3.1 million in 2023, then soared by 167.74% to $8.3 million in 2024.